Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3F8 in Metastatic Neuroblastoma in Second Remission
NCT00002458Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 1987
- Primary completion
- Sep 2001
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-GD2 monoclonal antibody 3F8 in neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 1987; status: completed.
02
Drugs
anti-GD2 monoclonal antibody 3F8
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00002458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002458.